Refine
Has Fulltext
- yes (131)
Is part of the Bibliography
- yes (131) (remove)
Year of publication
Document Type
- Journal article (118)
- Doctoral Thesis (13)
Language
- English (131) (remove)
Keywords
- DNA methylation (9)
- BRCA1 (5)
- DNA repair (5)
- breast cancer (5)
- heterochromatin (5)
- mutations (5)
- ovarian cancer (5)
- Anura (4)
- Fanconi anemia (4)
- Fanconi-Anämie (4)
- consortium (4)
- epigenetics (4)
- gene (4)
- 5-Methylcytosine (3)
- DNS-Reparatur (3)
- Epigenetik (3)
- Genmutation (3)
- Medizin (3)
- Methylierung (3)
- genetic modifiers (3)
- genetics (3)
- genome-wide association (3)
- immunofluorescence (3)
- investigators (3)
- methylation (3)
- sperm (3)
- susceptibility loci (3)
- zebrafish (3)
- 2B (2)
- ADHD (2)
- B chromosomes (2)
- BRCA2 (2)
- Candida albicans (2)
- DNA (2)
- Epigenetics (2)
- FISH (2)
- FSHD (2)
- Fabry disease (2)
- Fabry genotype (2)
- Fabry phenotype (2)
- Fanconi Anämie (2)
- HPP (2)
- Makuladegeneration (2)
- Netzhaut (2)
- RPE (2)
- SLX4 (2)
- STR profile (2)
- Spermium (2)
- TNAP (2)
- VMD2 (2)
- bisulfite pyrosequencing (2)
- blood (2)
- common variants (2)
- copy number variation (2)
- diagnosis (2)
- duchenne muscular dystrophy (2)
- exome sequencing (2)
- extracellular matrix (2)
- fetal programming (2)
- fibrosis (2)
- genetic diagnostics (2)
- genome (2)
- genomic imprinting (2)
- gestational diabetes mellitus (2)
- gridle muscular-dystrophy (2)
- hearing impairment (2)
- hearing loss (2)
- hepatic stellate cell (2)
- hereditary breast and ovarian cancer (2)
- hypophosphatasia (2)
- intellectual disability (2)
- liver (2)
- microcephaly (2)
- mineralization (2)
- modifiers (2)
- mutation (2)
- myofibrillar myopathy (2)
- myofibroblast (2)
- myopathy (2)
- nervous system (2)
- next generation sequencing (2)
- next generation sequencing (NGS) (2)
- protein (2)
- sensory neuropathy (2)
- sex chromosomes (2)
- single-nucleotide polymorphisms (2)
- somatic mosaicism (2)
- spectral karyotyping (2)
- sperm DNA methylation (2)
- survival (2)
- variants (2)
- whole exome sequencing (2)
- (classical and atypical) Werner syndrome (1)
- 3D modeling (1)
- 3R (1)
- 5-methylcytosine (1)
- A chromosomes (1)
- AFLP (1)
- AKT-signaling (1)
- ALPL (1)
- AMD (1)
- ART outcome (1)
- ATM gene (1)
- Age-related macular degeneration (1)
- Allophrynidae (1)
- Alzheimer's disease (1)
- Alzheimerkrankheit (1)
- Anticoagulants (1)
- Asisted Reproduction (1)
- Aspergillus fumigatus (1)
- Autism (1)
- Autism spectrum disorders (1)
- Autismus (1)
- B4GALT7 gene (1)
- BMD (1)
- BRCA1/2 (1)
- BRIP1 gene (1)
- Best Disease (1)
- Best-Krankheit (1)
- Bioinformatics (1)
- Blasentumor (1)
- BrdU replication banding pattern (1)
- BrdU/dT replication banding (1)
- Brustkrebs (1)
- CAGSSS (1)
- CDC14A (1)
- CIN (1)
- CLRN2 (1)
- COVID-19 (1)
- CRISPR-Cas Systems (1)
- CRISPR/Cas9 (1)
- Centrolenidae (1)
- Charcot-Marie-Tooth neuropathy 1A (1)
- Checkpoints (1)
- Chromosomal instability (1)
- Chromosomenbruch (1)
- Coagulation factor IX (1)
- Coexpression (1)
- Cognitive control (1)
- Copy number variation (1)
- Cortex (1)
- Coumarin (1)
- Cranial sutures (1)
- D4Z4 partial deletion (1)
- DFNB32 (1)
- DFNB68 (1)
- DLX5/6 (1)
- DM2 (1)
- DNA Methylation (1)
- DNA Reparatur (1)
- DNA damage (1)
- DNA double-strand break (1)
- DNA methylation dynamics (1)
- DNA methyltransferase gene (1)
- DNA repair defect (1)
- DNA-Instabilitätssyndrom (1)
- DNA-Methylation (1)
- DNA-Quervernetzung (1)
- DNA-repair (1)
- DNA-repair genes (1)
- DNMT3B (1)
- DYNC1I1 (1)
- Damage (1)
- Deflazacort (1)
- Down syndrome (1)
- Duchenne dystrphy (1)
- Duchenne muscular dystrophy (1)
- ERCC1-XPF (1)
- ERCC4 (1)
- Embryos (1)
- Enhancer elements (1)
- Environment (1)
- Epigenotypus (1)
- Epimutation (1)
- Erbkrankheit (1)
- Evans syndrome (1)
- Extracellular matrix (1)
- FA (1)
- FANCA (1)
- FANCD2 (1)
- FANCP (1)
- Familial Beckwith-Wiedemann syndrome (1)
- Fanconi Anemia (1)
- Fanconi anaemia (1)
- Fanconi-anemia subtype (1)
- Fetal brain development (1)
- Fluorescence in situ hybridization (1)
- Fourthcorner analysis (1)
- Frontal cortex (1)
- GTL2 (1)
- Gecko (1)
- Gen (1)
- Gene-expression (1)
- Genes (1)
- Genetik (1)
- Genome (1)
- Genotype-phenotype association (1)
- Genotype–phenotype correlations (1)
- Hereditary breast cancer (1)
- High-throughput data (1)
- Hindbrain (1)
- Histologic grade (1)
- Holliday junction reolvass (1)
- Human prefrontal cortex (1)
- Hypophosphatasia (1)
- IARS2 (1)
- ICF2 (1)
- ICL (1)
- ICSI (1)
- IGF2-H19 (1)
- II citrullinemia (1)
- IMSI (1)
- Imprinting (1)
- Indian muntjac (1)
- Induced Pluripotent Stem Cells (1)
- Instability (1)
- KRAS (1)
- Keimzell- und Embryonalentwicklung (1)
- LGMDR5 (1)
- Limb development (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Long-term follow-up (1)
- MCPH1 (1)
- MEK/ERK-signaling (1)
- MFM (1)
- Male breast cancer (1)
- Malignant neoplasms (1)
- Mausmodell (1)
- Membranproteine (1)
- Methylome (1)
- Microarray analysis (1)
- Miyoshi myopathy (1)
- Molecular approaches (1)
- Molekularbiologie (1)
- Molekulargenetik (1)
- Morbus Best (1)
- Mosaizismus (1)
- Mucopolysaccharidosis IIIa (1)
- Multivariate analysis (1)
- Mutation (1)
- Mutationen (1)
- Mutationsanalyse (1)
- N170 (1)
- NEIL2 (1)
- Neanderthal (1)
- Neisseria meningitidis (1)
- Neuroepigenomics (1)
- Neurons (1)
- Next generation sequencing (1)
- OGG1 (1)
- Ordination methods (1)
- Ovarian (1)
- P100 (1)
- PCR (1)
- Pakistan (1)
- Parent-of-origin (1)
- Paternal age effect (1)
- Pathology (1)
- Patterns (1)
- Pigmentepithel (1)
- Pompe disease (1)
- RAD50-Defizienz (1)
- RAD51C (1)
- RLQ analysis (1)
- RNA-Seq analysis (1)
- RPE specific genes (1)
- Renal abnormalities (1)
- Repair (1)
- Reproduktionsmedizin (1)
- Retina (1)
- Reversion (1)
- Robertsonian translocation chromosomes (1)
- S1PR2 (1)
- SARS-CoV-2 (1)
- SH3 domain (1)
- SHFM (1)
- SKY analysis (1)
- SLC2A3 (1)
- SNP array (1)
- SNP-microarray (1)
- Schizophrenia (1)
- Selective attention (1)
- Self-renewal (1)
- Senile Makuladegeneration (1)
- Senile Makuladegeneration / Pigmentepithel / Genexpression (1)
- Skull (1)
- Somites (1)
- Spermien (1)
- Stability (1)
- Staphylococcus aureus (1)
- Suicidal behavior (1)
- Susceptibility (1)
- TMEM43 (1)
- TRIM32 (1)
- TYPE-2 (1)
- Terminal 4q deletion syndrome (1)
- Th17 (1)
- Transcription (1)
- Transcription regulation (1)
- Transcriptome (1)
- Transcriptomics (1)
- Transkription <Genetik> (1)
- Transkriptome (1)
- Tregs (1)
- UBZ (1)
- Urodela (1)
- Usher syndrome (1)
- VKORC1 (1)
- Vater (1)
- Visualization (1)
- Vitamin K epoxide reductase (1)
- Väterliches Alter (1)
- WDR62 mutation (1)
- Warfarin (1)
- Working memory (1)
- X chromosome (1)
- X-chromosomal inactivation (1)
- X. laevis-type karyotype (1)
- X. tropicalis-type karyotype (1)
- Xenopus (1)
- Xenopus laevis (1)
- Xenopus tropicalis (1)
- Y chromosome degeneration (1)
- ZBTB24 (1)
- ZBTB24 mutations (1)
- ZNF365 (1)
- ZW sex chromosomes (1)
- Zebrafish (1)
- Zellzyklus (1)
- abnormalities (1)
- adenoma (1)
- adrenal insufficiency (1)
- age at onset (1)
- age-related differentially methylated regions (ageDMRs) (1)
- aldehydes (1)
- alleles (1)
- allopolyploidy (1)
- alternative methods (1)
- alu elements (1)
- alzheimers disease (1)
- amphiphysin-2 BIN1 (1)
- amplicon sequencing (1)
- antidepressants (1)
- anxiety disorders (1)
- apoptosis (1)
- arrhythmogenic cardiomyopathy (1)
- asexual reproduction (1)
- assistierte Reproduktion (1)
- association (1)
- autism (1)
- autophagy (1)
- autopolyploidy (1)
- autosomal recessive hearing loss (1)
- autosomal recessive non-synstromic hearing loss (1)
- banding analyses (1)
- bcl-2 associated athanogene protein 3 (1)
- behavior (1)
- bestrophin (1)
- bioinformatics and computational biology (1)
- bleding disorders other than hemophilia (1)
- bone marrow failure syndrome (1)
- bovine (1)
- breast cancer predisposition genes (1)
- breast neoplasms (1)
- cadherins (1)
- cancer treatment (1)
- candida genome database (1)
- candidate genes (1)
- cardiogenetics (1)
- cardiomyopathy (1)
- case report (1)
- cataracts (1)
- cell (1)
- cell death (1)
- cell division (1)
- cell wall (1)
- centromeric instability (1)
- childhood cancer (1)
- children (1)
- chip-seq (1)
- chromosomal abnormality (1)
- chromosomal instability (1)
- chromosomale Instabilität (1)
- chromosome evolution (1)
- chromosome inversion (1)
- chromosome staining (1)
- chromsomal instability (1)
- classification (1)
- combined retinal dystrophy (1)
- comparative genomics (1)
- complex chromosome rearrangements (1)
- complex disorders (1)
- complex traits (1)
- computational prediction (1)
- congenital heart-deffects (1)
- congenital myopathy (1)
- connective tissue disorder (1)
- consanguinity (1)
- copy-number variation (1)
- craniosynostosis (1)
- cross-link repair (1)
- cytokinesis (1)
- cytotoxicity (1)
- damage (1)
- danazol (1)
- danio rerio (1)
- database (1)
- deafness (1)
- deep bisulfite sequencing (1)
- deficiency (1)
- deletion (1)
- design (1)
- developmental origins hypothesis (1)
- diagnostic delay (1)
- differentially methylated region (1)
- differentiation (1)
- diploidization (1)
- disease (1)
- disruption project (1)
- double trouble (1)
- duplication (1)
- duplication-deficiency (1)
- dysferlinopathy (1)
- dystrophin (1)
- eExons (1)
- early respiratory-failure (1)
- elective surgery (1)
- elements (1)
- embryos (1)
- endonuclease (1)
- epigenetic heterogeneity (1)
- epimutation (1)
- epithelial cells (1)
- establishment (1)
- euchromatin (1)
- evolutionary biology (1)
- evolutionary fixation (1)
- expansion (1)
- expression signature (1)
- extreme phenotypes (1)
- facial anomalies (1)
- facioscapulohumeral muscular dystrophy (1)
- familial breast cancer (1)
- families (1)
- fanconi anemia (1)
- fanconi-anemia (1)
- features (1)
- female (1)
- female Fabry patients (1)
- fetal brain development (1)
- fetal cord blood (1)
- fetal overnutrition (1)
- fibroblasts (1)
- filamin C (1)
- fine-scale mapping (1)
- fish (1)
- flies (1)
- frameshift (1)
- frontal cortex (1)
- functional analysis (1)
- functional modules (1)
- geckos (1)
- gene mutations (1)
- genetic causes of cancer (1)
- genetic diagnosis (1)
- genetic heterogeneity (1)
- genetic interaction networks (1)
- genetic loci (1)
- genetic skeletal disorders (1)
- genetic susceptibility (1)
- genetic testing (1)
- genetic variants (1)
- genome sequencing (1)
- genome-wide association study (GWAS) (1)
- genome-wide linkage analysis (1)
- genomic analysis (1)
- genomic libraries (1)
- genomics (1)
- genotype-phenotype correlation (1)
- genotyping arrays (1)
- germline mutations (1)
- glycogenin 1 (1)
- gonads (1)
- granulomas (1)
- great dane (1)
- growth failure (1)
- growth hormone deficiency (1)
- gynogenesis (1)
- hand/foot malformation (1)
- haplogroups (1)
- haploinsufficiency (1)
- helicase BRIP1 (1)
- hematology (1)
- hemostasis and thrombosis (1)
- hereditary hearing loss (1)
- hereditary motor (1)
- hereditary motor and sensory neuropathy (1)
- heterogeneity (1)
- heteromorphic sex chromosomes (1)
- heterozygote (1)
- histological subtype (1)
- homoeologous chromosomes (1)
- hormone-related protein (1)
- host cells (1)
- human disease (1)
- human evolution (1)
- humans (1)
- hybridogenesis (1)
- hypermethylated DNA (1)
- hypermethylation (1)
- illumina (1)
- immune thrombocytopenia (1)
- immunodeficiency (1)
- imprinting control region (1)
- in situ hybridization (1)
- in vitro model (1)
- incidence (1)
- induced pluripotent stem cells (1)
- infinium HumanOmni1-Quad (1)
- inflammation (1)
- inflammatory diseases (1)
- inherited myopathy (1)
- insulin treatment (1)
- intergenerational contraction (1)
- interolog (1)
- interstrand crosslink (1)
- intrachromosomal telomeric sequences (1)
- inversion (1)
- italian patients (1)
- karyotype evolution (1)
- kinase signaling (1)
- limb development (1)
- linked myotubular myopathy (1)
- live-born (1)
- lymphoma (1)
- lyso‐Gb3 (1)
- macrophages (1)
- macular degeneration (1)
- maintenance (1)
- male breast cancer (1)
- malformations (1)
- mammalian male germline (1)
- mammographic density (1)
- meiosis (1)
- meiotic chromosomes (1)
- meiotic ‘superring’ (1)
- membrane curvature (1)
- membrane repair (1)
- mental retardation (1)
- metabolic disease (1)
- metabolism (1)
- methylation array (1)
- mice (1)
- microdeletion syndrome (1)
- microdissection (1)
- midbody (1)
- middle aged (1)
- mineraliztion (1)
- missense mutations (1)
- mitotic chromosomes (1)
- mixed hearing loss (1)
- mixed mutation mechanisms (1)
- miyoshi myopathy (1)
- model (1)
- moderate-penetrance genes (1)
- molecular analysis (1)
- molecular cloning (1)
- monoubiquitination (1)
- monozygotic twins (1)
- mosaicism (1)
- mouse (1)
- mouse model (1)
- multiple diseases (1)
- multiple myeloma (1)
- muscle disease (1)
- muscle strength (1)
- muscular dystrophy (1)
- muscular-dystrophy (1)
- mutation analysis (1)
- natural variation (1)
- network analysis (1)
- network inference (1)
- networks (1)
- neurodevelopmental disorders / genetics (1)
- neuromuscular disease (1)
- neurotransmission (1)
- neutrophils (1)
- next-generation sequencing (1)
- next-generation-sequencing (1)
- nomenclature (1)
- non-mosaic (1)
- non-sense mediated mRNA decay (1)
- nonspecific alkaline-phosphae (1)
- oocytes (1)
- organ toxicity (1)
- overlapping syndrome (1)
- oxidative stress (1)
- p.R245H (1)
- p.S298P (1)
- painful (1)
- panel sequencing (1)
- panic disorder (1)
- paternal age (1)
- paternal age effect (1)
- paternal introgression (1)
- pathogen-host interaction (PHI) (1)
- pathogenicity (1)
- pathway (1)
- patient (1)
- penetrance (1)
- phalloidin stain (1)
- phenotype (1)
- phosphoproteome (1)
- platelet disorders (1)
- polymerase chain reaction (1)
- polymorphism (1)
- polyneuropathy (1)
- polyploidization (1)
- polyploidy (1)
- population (1)
- potential role (1)
- prednisone (1)
- premature aging (1)
- premutation (1)
- prevalence (1)
- promoter methylation (1)
- promotes (1)
- protein aggregation (1)
- protein interaction database (1)
- protein-protein interaction (1)
- proteins (1)
- proteomic signature (1)
- protocadherin gamma cluster (1)
- recessive inheritance (1)
- reciprocal translocation (1)
- recombination (1)
- recurrence (1)
- regulatory T cells (1)
- regulatory mutations (1)
- reproduction (1)
- requency (1)
- reversion (1)
- rhodamine–phalloidin stain (1)
- risk (1)
- sarcoglycanopathy (1)
- sarcotubular myopathy (1)
- screening (1)
- secondary cancer (1)
- segmental progeria (1)
- selection (1)
- sensorineural hearing loss (1)
- sequence alignment (1)
- sequence assembly tools (1)
- sex chromosome evolution (1)
- sex linked pigmentation pattern (1)
- sex ratio (1)
- sexual antagonistic genes (1)
- skeletal dysplasia (1)
- skeletal muscle (1)
- skeletal myopathy (1)
- sky kinases (1)
- species-specific epigenetic marks (1)
- spinal muscular atrophy (1)
- splicing (1)
- spondylodysplastic Ehlers-Danlos syndrome (1)
- steroids (1)
- stress fibers (1)
- structural genome variations (1)
- submicroscopic chromosome rearrangement (1)
- subtypes (1)
- suppression (1)
- susceptibility (1)
- susceptibility alleles (1)
- susceptibility gene (1)
- synaptonemal complex (1)
- systemic sclerosis (1)
- targeted gene panel (1)
- teeth (1)
- telomere length (1)
- telomeres (1)
- temperature (1)
- testes (1)
- testosterone (1)
- therapy (1)
- throat (1)
- tinnitus (1)
- tissue-specific enhancers (1)
- transcription deficiency (1)
- transcriptional regulation (1)
- transcriptome (1)
- transgenic animals (1)
- transporter gene SLC2A3 (1)
- transposable elements (1)
- treatment guidelines (1)
- triple-negative breast cancer (1)
- triplosufficiency (1)
- trisomy 21 (1)
- trisomy 22 (1)
- tumor subtypes (1)
- tumor-suppressor (1)
- twin study (1)
- type II esophageal achalasia (1)
- ubiquitin (1)
- vacuolar myopathy (1)
- ventilation (1)
- vertebrate (1)
- whole genome sequencing (1)
- whole genome sequencing (WGS) (1)
- whole-exome sequencing (1)
- α‐GalA 3D‐structure (1)
Institute
- Institut für Humangenetik (131) (remove)
Sonstige beteiligte Institutionen
- Comprehensive Hearing Center, Department of ORL, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Würzburg, Germany (1)
- DNA Analytics Core Facility, Biocenter, University of Würzburg, Würzburg, Germany (1)
- Department of Animal Ecology and Tropical Biology, University of Würzburg, Würzburg, Germany (1)
- Maastricht University, Maastricht, the Netherlands (1)
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disease caused by heterozygous missense mutations within the gene encoding for the nuclear envelope protein transmembrane protein 43 (TMEM43). The disease is characterized by myocyte loss and fibro-fatty replacement, leading to life-threatening ventricular arrhythmias and sudden cardiac death. However, the role of TMEM43 in the pathogenesis of ACM remains poorly understood. In this study, we generated cardiomyocyte-restricted transgenic zebrafish lines that overexpress eGFP-linked full-length human wild-type (WT) TMEM43 and two genetic variants (c.1073C>T, p.S358L; c.332C>T, p.P111L) using the Tol2-system. Overexpression of WT and p.P111L-mutant TMEM43 was associated with transcriptional activation of the mTOR pathway and ribosome biogenesis, and resulted in enlarged hearts with cardiomyocyte hypertrophy. Intriguingly, mutant p.S358L TMEM43 was found to be unstable and partially redistributed into the cytoplasm in embryonic and adult hearts. Moreover, both TMEM43 variants displayed cardiac morphological defects at juvenile stages and ultrastructural changes within the myocardium, accompanied by dysregulated gene expression profiles in adulthood. Finally, CRISPR/Cas9 mutants demonstrated an age-dependent cardiac phenotype characterized by heart enlargement in adulthood. In conclusion, our findings suggest ultrastructural remodeling and transcriptomic alterations underlying the development of structural and functional cardiac defects in TMEM43-associated cardiomyopathy.
Copy number variants of SLC2A3, which encodes the glucose transporter GLUT3, are associated with several neuropsychiatric and cardiac diseases. Here, we report the successful reprogramming of peripheral blood mononuclear cells from two SLC2A3 duplication and two SLC2A3 deletion carriers and subsequent generation of two transgene-free iPSC clones per donor by Sendai viral transduction. All eight clones represent bona fide hiPSCs with high expression of pluripotency genes, ability to differentiate into cells of all three germ layers and normal karyotype. The generated cell lines will be helpful to enlighten the role of glucometabolic alterations in pathophysiological processes shared across organ boundaries.
Background
Dystrophinopathies caused by variants in the DMD gene are a well‐studied muscle disease. The most common type of variant in DMD are large deletions. Very rarely reported forms of variants are chromosomal translocations, inversions and deep intronic variants (DIVs) because they are not detectable by standard diagnostic techniques (sequencing of coding sequence, copy number variant detection). This might be the reason that some clinically and histologically proven dystrophinopathy cases remain unsolved.
Methods
We used whole genome sequencing (WGS) to screen the entire DMD gene for variants in one of two brothers suffering from typical muscular dystrophy with strongly elevated creatine kinase levels.
Results
Although a pathogenic DIV could not be detected, we were able to identify a pericentric inversion with breakpoints in DMD intron 44 and Xq13.3, which could be confirmed by Sanger sequencing in the index as well as in his brother and mother. As this variation affects a major part of DMD it is most likely disease causing.
Conclusion
Our findings elucidate that WGS is capable of detecting large structural rearrangements and might be suitable for the genetic diagnostics of dystrophinopathies in the future. In particular, inversions might be a more frequent cause for dystrophinopathies as anticipated and should be considered in genetically unsolved dystrophinopathy cases.
Human growth has an estimated heritability of about 80%-90%. Nevertheless, the underlying cause of shortness of stature remains unknown in the majority of individuals. Genome-wide association studies (GWAS) showed that both common single nucleotide polymorphisms and copy number variants (CNVs) contribute to height variation under a polygenic model, although explaining only a small fraction of overall genetic variability in the general population. Under the hypothesis that severe forms of growth retardation might also be caused by major gene effects, we searched for rare CNVs in 200 families, 92 sporadic and 108 familial, with idiopathic short stature compared to 820 control individuals. Although similar in number, patients had overall significantly larger CNVs \((p-value <1 x 10^{-7})\). In a gene-based analysis of all non-polymorphic CNVs >50 kb for gene function, tissue expression, and murine knock-out phenotypes, we identified 10 duplications and 10 deletions ranging in size from 109 kb to 14 Mb, of which 7 were de novo (p < 0.03) and 13 inherited from the likewise affected parent but absent in controls. Patients with these likely disease causing 20 CNVs were smaller than the remaining group (p < 0.01). Eleven (55%) of these CNVs either overlapped with known microaberration syndromes associated with short stature or contained GWAS loci for height. Haploinsufficiency (HI) score and further expression profiling suggested dosage sensitivity of major growth-related genes at these loci. Overall 10% of patients carried a disease-causing CNV indicating that, like in neurodevelopmental disorders, rare CNVs are a frequent cause of severe growth retardation.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
(2020)
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
Background:
The etiology of secondary cancer in childhood cancer survivors is largely unclear. Exposure of normal somatic cells to radiation and/or chemotherapy can damage DNA and if not all DNA lesions are properly fixed, the mis-repair may lead to pathological consequences. It is plausible to assume that genetic differences, i.e. in the pathways responsible for cell cycle control and DNA repair, play a critical role in the development of secondary cancer.
Methodology/Findings:
To identify factors that may influence the susceptibility for second cancer formation, we recruited 20 individuals who survived a childhood malignancy and then developed a second cancer as well as 20 carefully matched control individuals with childhood malignancy but without a second cancer. By antibody microarrays, we screened primary fibroblasts of matched patients for differences in the amount of representative DNA repair-associated proteins. We found constitutively decreased levels of RAD9A and several other DNA repair proteins in two-cancer patients, compared to one-cancer patients. The RAD9A protein level increased in response to DNA damage, however to a lesser extent in the two-cancer patients. Quantification of mRNA expression by real-time RT PCR revealed lower RAD9A mRNA levels in both untreated and 1 Gy gamma-irradiated cells of two-cancer patients.
Conclusions/Significance:
Collectively, our results support the idea that modulation of RAD9A and other cell cycle arrest and DNA repair proteins contribute to the risk of developing a second malignancy in childhood cancer patients.
Background: The etiology of secondary cancer in childhood cancer survivors is largely unclear. Exposure of normal somatic cells to radiation and/or chemotherapy can damage DNA and if not all DNA lesions are properly fixed, the mis-repair may lead to pathological consequences. It is plausible to assume that genetic differences, i.e. in the pathways responsible for cell cycle control and DNA repair, play a critical role in the development of secondary cancer. Methodology/Findings: To identify factors that may influence the susceptibility for second cancer formation, we recruited 20 individuals who survived a childhood malignancy and then developed a second cancer as well as 20 carefully matched control individuals with childhood malignancy but without a second cancer. By antibody microarrays, we screened primary fibroblasts of matched patients for differences in the amount of representative DNA repair-associated proteins. We found constitutively decreased levels of RAD9A and several other DNA repair proteins in two-cancer patients, compared to onecancer patients. The RAD9A protein level increased in response to DNA damage, however to a lesser extent in the twocancer patients. Quantification of mRNA expression by real-time RT PCR revealed lower RAD9A mRNA levels in both untreated and 1 Gy c-irradiated cells of two-cancer patients. Conclusions/Significance: Collectively, our results support the idea that modulation of RAD9A and other cell cycle arrest and DNA repair proteins contribute to the risk of developing a second malignancy in childhood cancer patients.
Background
Germline mutations in the BRIP1 gene have been described as conferring a moderate risk for ovarian cancer (OC), while the role of BRIP1 in breast cancer (BC) pathogenesis remains controversial.
Methods
To assess the role of deleterious BRIP1 germline mutations in BC/OC predisposition, 6341 well-characterized index patients with BC, 706 index patients with OC, and 2189 geographically matched female controls were screened for loss-of-function (LoF) mutations and potentially damaging missense variants. All index patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germline testing and tested negative for pathogenic BRCA1/2 variants.
Results
BRIP1 LoF mutations confer a high OC risk in familial index patients (odds ratio (OR) = 20.97, 95% confidence interval (CI) = 12.02–36.57, P < 0.0001) and in the subgroup of index patients with late-onset OC (OR = 29.91, 95% CI = 14.99–59.66, P < 0.0001). No significant association of BRIP1 LoF mutations with familial BC was observed (OR = 1.81 95% CI = 1.00–3.30, P = 0.0623). In the subgroup of familial BC index patients without a family history of OC there was also no apparent association (OR = 1.42, 95% CI = 0.70–2.90, P = 0.3030). In 1027 familial BC index patients with a family history of OC, the BRIP1 mutation prevalence was significantly higher than that observed in controls (OR = 3.59, 95% CI = 1.43–9.01; P = 0.0168). Based on the negative association between BRIP1 LoF mutations and familial BC in the absence of an OC family history, we conclude that the elevated mutation prevalence in the latter cohort was driven by the occurrence of OC in these families. Compared with controls, predicted damaging rare missense variants were significantly more prevalent in OC (P = 0.0014) but not in BC (P = 0.0693) patients.
Conclusions
To avoid ambiguous results, studies aimed at assessing the impact of candidate predisposition gene mutations on BC risk might differentiate between BC index patients with an OC family history and those without. In familial cases, we suggest that BRIP1 is a high-risk gene for late-onset OC but not a BC predisposition gene, though minor effects cannot be excluded.
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
(2013)
Background: Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B).
Methods: We assessed the one-year-natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a double-blind, placebo-controlled cross-over trial. After one year of natural course without intervention, 25 patients with genetically defined dysferlinopathy were randomized to receive deflazacort and placebo for six months each (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six) in one of two treatment sequences. Results: During one year of natural course, muscle strength declined about 2% as measured by CIDD (Clinical Investigation of Duchenne Dystrophy) score, and 76 Newton as measured by hand-held dynamometry. Deflazacort did not improve muscle strength. In contrast, there is a trend of worsening muscle strength under deflazacort treatment, which recovers after discontinuation of the study drug. During deflazacort treatment, patients showed a broad spectrum of steroid side effects.
Conclusion: Deflazacort is not an effective therapy for dysferlinopathies, and off-label use is not warranted. This is an important finding, since steroid treatment should not be administered in patients with dysferlinopathy, who may be often misdiagnosed as polymyositis.
Background
Although Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene (GLA), women may develop severe symptoms. We investigated X-chromosomal inactivation patterns (XCI) as a potential determinant of symptom severity in FD women.
Patients and Methods
We included 95 women with mutations in GLA (n = 18 with variants of unknown pathogenicity) and 50 related men, and collected mouth epithelial cells, venous blood, and skin fibroblasts for XCI analysis using the methylation status of the androgen receptor gene. The mutated X-chromosome was identified by comparison of samples from relatives. Patients underwent genotype categorization and deep clinical phenotyping of symptom severity.
Results
43/95 (45%) women carried mutations categorized as classic. The XCI pattern was skewed (i.e., ≥75:25% distribution) in 6/87 (7%) mouth epithelial cell samples, 31/88 (35%) blood samples, and 9/27 (33%) skin fibroblast samples. Clinical phenotype, α-galactosidase A (GAL) activity, and lyso-Gb3 levels did not show intergroup differences when stratified for X-chromosomal skewing and activity status of the mutated X-chromosome.
Conclusions
X-inactivation patterns alone do not reliably reflect the clinical phenotype of women with FD when investigated in biomaterial not directly affected by FD. However, while XCI patterns may vary between tissues, blood frequently shows skewing of XCI patterns.